v3.22.2.2
Identifiable Intangible Assets (Tables)
 9 Months Ended
Oct. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
October 2, 2022December 31, 2021
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights$72,818 $(55,309)$17,509 $73,346 $(53,732)$19,614 
Brands922 (832)90 922 (807)115 
Licensing agreements and other2,296 (1,373)923 2,284 (1,299)985 
76,036 (57,514)18,522 76,552 (55,838)20,714 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D(a)
7,829 7,829 3,092 3,092 
Licensing agreements and other(a)
972 972 513 513 
9,629 9,629 4,432 4,432 
Identifiable intangible assets(a), (b)
$85,665 $(57,514)$28,151 $80,984 $(55,838)$25,146 
(a)The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
(b)The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
Schedule of Indefinite Lived Intangible Assets
The following summarizes the components of Identifiable intangible assets:
October 2, 2022December 31, 2021
(MILLIONS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights$72,818 $(55,309)$17,509 $73,346 $(53,732)$19,614 
Brands922 (832)90 922 (807)115 
Licensing agreements and other2,296 (1,373)923 2,284 (1,299)985 
76,036 (57,514)18,522 76,552 (55,838)20,714 
Indefinite-lived intangible assets
Brands827 827 827 827 
IPR&D(a)
7,829 7,829 3,092 3,092 
Licensing agreements and other(a)
972 972 513 513 
9,629 9,629 4,432 4,432 
Identifiable intangible assets(a), (b)
$85,665 $(57,514)$28,151 $80,984 $(55,838)$25,146 
(a)The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena (see Note 2A), and for IPR&D, is partially offset by an impairment (see Note 4).
(b)The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.
Schedule of Goodwill
The following summarizes the changes in the carrying amount of Goodwill:
(MILLIONS)
Total(a)
Balance, January 1, 2022
$49,208 
Additions(b)
1,029 
Other(c)
(797)
Balance, October 2, 2022
$49,441 
(a)All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.
(b)Additions relate to our acquisition of Arena. See Note 2A.
(c)Other represents the impact of foreign exchange.